【摘要】 目的通过研究抑郁症患者25-羟基维生素D₃[25（OH）D₃]与汉密尔顿抑郁量表（HAMD）评分之间的关系,探讨25（OH）D₃在抑郁症治疗过程中的应用价值。方法将108例抑郁症患者随机分为观察组和对照组,每组各54例。所有患者均常规服用抗抑郁药物帕罗西汀,观察组加服维生素D₃（5 000 U/d）。对所有患者治疗前和治疗1、3、5、7周进行HAMD评分,同时测定25（OH）D₃水平。结果观察组治疗3、5和7周的血清25（OH）D₃水平均明显高于对照组（P<0.05）。观察组治疗5、7周的HAMD评分均明显低于对照组（P<0.05）。观察组HAMD评分与血清25（OH）D₃水平呈负相关（r=-0.97,P<0.01）。结论抑郁症患者在服用常规抗抑郁药物基础上加服维生素D可改善抑郁症的治疗效果,血清25（OH）D₃水平可作为抑郁疗效监测的潜在指标。更多还原

【Abstract】 Objective To investigate the relationship of serum 25-hydroxyvitamin D₃ [25（OH）D₃] in the treatment of depression and Hamilton Rating Scale for Depression（HAMD） score,and to evaluate the role of serum 25（OH）D₃ in the treatment of depression. Methods A total of 108 patients with depression were randomly classified into observation group（54 cases） and control group（54 cases）. All patients were given antidepressant Pa Rossi Dean regularly,and the observation group was given vitamin D₃ as well. The analysis of HAMD score was performed for all the patients before treatment and after treatment for 1,3,5 and 7 weeks. The levels of serum 25（OH）D₃ in the 2 groups were determined. Results After treatment for 3,5 and 7 weeks,the levels of serum 25（OH）D₃ in observation group were higher than that in control group（P<0.05）. After treatment for 5 and 7 weeks,HAMD scores in observation group were lower than that in control group（P<0.05）. HAMD score and serum 25（OH）D₃ in observation group had a negative correlation（r=-0.97,P<0.01）. Conclusions For patients with depression,taking vitamin D on the basis of conventional antidepressants can improve the effectiveness of depression treatment. Serum 25（OH）D₃ can be used as a potential indicator of depression efficacy monitoring.更多还原